Core Viewpoint - Addex Therapeutics reported a significant decrease in net results for the third quarter of 2024, with a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million in the previous quarter, primarily due to a nonrecurring gain from a business sale in the second quarter [2][3] Financial Performance - The provisional net loss for Q3 2024 was CHF 1.5 million, a decrease of CHF 14.4 million from the net profit of CHF 12.9 million in Q2 2024 [2] - For the nine-month period ending September 30, 2024, Addex reported a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ending June 30, 2024 [3] - As of September 30, 2024, Addex's cash position was CHF 3.3 million [3] Upcoming Events - Addex is scheduled to release its third quarter 2024 financial results on November 22, 2024, with a teleconference and webcast for investors and analysts [4]

Core Viewpoint - Addex Therapeutics Ltd. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks Consensus Estimate for Addex Therapeutics for the fiscal year ending December 2024 is projected at $0.49 per share, reflecting a 102.6% increase from the previous year [5]. - Over the past three months, the consensus estimate has risen by 104.2%, indicating a strong upward trend in earnings expectations [5]. Impact of Earnings Estimates - Changes in earnings estimates are strongly correlated with near-term stock price movements, primarily due to institutional investors adjusting their valuations based on these estimates [3]. - An increase in earnings estimates typically leads to higher fair value assessments by institutional investors, resulting in buying or selling activity that influences stock prices [3]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and has shown a strong track record of performance [4]. - Stocks rated Zacks Rank 1 have generated an average annual return of +25% since 1988, highlighting the effectiveness of the system in identifying potential investment opportunities [4]. Positioning of Addex Therapeutics - The upgrade to Zacks Rank 2 places Addex Therapeutics in the top 20% of Zacks-covered stocks, suggesting a favorable position for potential market-beating returns in the near term [7].

Financial Data and Key Metrics Changes - The company recognized $0.1 million of income in Q2 2024, down from $0.6 million in Q2 2023, primarily from research funding with Indivior [23][24] - Continuing R&D expenses remained stable at $0.3 million in Q2 2024 compared to Q2 2023 [24] - General and administrative expenses were stable at $0.7 million in Q2 2024 compared to Q2 2023 [24] - The company completed Q2 2024 with CHF3.8 million in cash, with current liabilities decreasing by CHF1.9 million compared to June 30, 2023 [24][25] Business Line Data and Key Metrics Changes - The GABAB PAM program has made significant progress, with Indivior selecting a compound for development in substance use disorders, expecting to start IND enabling studies in H1 2025 [7][9] - The independent GABAB PAM program for chronic cough is expected to start IND enabling studies in 2025, pending financing [9][18] Market Data and Key Metrics Changes - The company launched Neurosterix with a Series A financing of $63 million, securing a 20% equity interest in the new entity [6][22] - The Neurosterix transaction is expected to alleviate financing pressures on Addex, allowing for the advancement of its preclinical portfolio [22][30] Company Strategy and Development Direction - The company aims to advance its GABAB PAM program for chronic cough and is exploring various clinical indications, including refractory chronic cough and COPD [29][30] - The strategic spin-out of Neurosterix is seen as a transformative move, strengthening the balance sheet and securing financing for preclinical development [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of dipraglurant for brain injury recovery, highlighting the large unmet medical need in post-stroke rehabilitation [10][11] - The company is focused on achieving better efficacy and tolerability compared to existing treatments in the chronic cough space [32][34] Other Important Information - The company has divested its allosteric modulation technology platform but retains a service agreement with Neurosterix to access necessary skills [22] - The company is on track to complete IND-enabling studies for Neurosterix compounds by mid-next year, with plans to file INDs for Phase 1 trials in the second half of 2025 [40] Q&A Session Summary Question: What specific clinical indications are being considered for the chronic cough program? - The company is considering refractory and unexplained chronic cough, as well as COPD or IPF-related chronic cough [29] Question: Are MED and ED50 used interchangeably? - No, MED refers to minimum effective dose, while ED50 is the effective dose that achieves 50% of the effect [30] Question: What comparator molecules will be used in the chronic cough program? - The company will consider baclofen and other GABAB PAMs, aiming for similar or better efficacy with improved tolerability [32] Question: Will Camlipixant be a competitor? - Yes, the company expects Camlipixant to be the standard-of-care by the time they reach later-stage development [33] Question: What are the prospects for the Neurosterix portfolio compounds? - The company anticipates completing IND-enabling studies in the middle of next year and filing INDs for Phase 1 trials in the second half of 2025 [40]

Core Insights - Addex Therapeutics reported a significant increase in provisional half-year and second quarter net results for 2024, primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024 [1][2] Financial Performance - The provisional net gain for the six-month period ended June 30, 2024, amounted to CHF 9.8 million, compared to a net loss of CHF 5.1 million for the same period in 2023, reflecting an increase of CHF 14.9 million [2] - The increase is attributed to gross proceeds of CHF 5.0 million received in cash from the business sale and a fair value of CHF 9.4 million for a 20% equity interest in Neurosterix US holdings LLC [2] - As of June 30, 2024, the cash position of the Group was CHF 3.8 million [2] Upcoming Events - The company plans to issue its Half-Year 2024 Financial Results on September 30, 2024, with a teleconference and webcast for investors, analysts, and media scheduled for the same day at 16:00 CEST [3] Company Overview - Addex Therapeutics is focused on developing novel small molecule allosteric modulators for neurological disorders, with its lead drug candidate, dipraglurant, under evaluation for brain injury recovery [5] - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, with IND enabling studies expected to start in H1 2025 [5] - Addex also holds a 20% equity interest in Neurosterix LLC, which is advancing various allosteric modulator programs [5]

Group 1 - Addex Therapeutics Ltd. Sponsored ADR (ADXN) has returned 86.9% year-to-date, significantly outperforming the average return of 10.1% for the Medical sector [2][3] - The Zacks Consensus Estimate for ADXN's full-year earnings has increased by 97% over the past 90 days, indicating stronger analyst sentiment and an improving earnings outlook [2] - Addex Therapeutics is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [1][2] Group 2 - Addex Therapeutics is part of the Medical - Drugs industry, which consists of 180 companies and currently ranks 99 in the Zacks Industry Rank, with the industry having lost about 2.3% year-to-date [3] - Boston Scientific (BSX), another outperforming Medical stock, has returned 40.8% year-to-date and belongs to the Medical - Products industry, which has moved up by 12.5% this year [2][3] - The Medical sector overall is ranked 4 in the Zacks Sector Rank, which evaluates the strength of individual sector groups [1]

Company Performance - Hain Celestial Group, Inc. reported fourth quarter adjusted earnings per share of 13 cents, exceeding the analyst consensus estimate of 8 cents, while quarterly revenues of $418.80 million fell short of the expected $421.2 million [2] - Ensysce Biosciences, Inc. shares surged 43% to $0.6190 after receiving a $14 million multi-year grant from the NIH for the development of its PF614-MPAR opioid [2] - Addex Therapeutics Ltd saw a 39% increase in shares to $10.40 following the selection of clinical candidates from its collaboration with Indivior, with potential earnings of up to $330 million [2] - VOXX International Corporation shares rose 70% to $4.8450 after announcing a strategic alternatives process to maximize valuation [2] Company Declines - Altisource Asset Management Corporation shares plummeted 48% to $1.2250 after announcing plans to voluntarily delist from the NYSE American LLC [3] - COSCIENS Biopharma Inc. shares fell 26% to $4.3350 following results from its Phase 3 DETECT-trial [3] - American Woodmark Corporation shares decreased by 10% to $89.93 after reporting worse-than-expected first-quarter results and projecting a decline in FY25 sales [3] Commodities - Oil prices decreased by 1.8% to $76.02, while gold prices fell by 0.2% to $2,550.90 [4] - Silver prices dropped by 0.1% to $29.97, whereas copper prices increased by 0.6% to $4.3085 [4] European Market Insights - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.17% and Germany's DAX rising 0.40% [5] - The German economy contracted by 0.1% quarter-over-quarter in Q2, following a 0.2% growth in Q1 [5] - The GfK Consumer Climate Indicator for Germany fell to -22.0 in September from a revised -18.6 in the previous period [5] Asian Market Insights - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.47% and Hong Kong's Hang Seng Index rising 0.43% [6] - Hong Kong's trade deficit narrowed to $21.8 billion in July from a $30 billion gap in the same month last year, as exports increased more than imports [6]

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Sympos ...

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] - GABAB receptors are important in the cough neural circuit, and targeting them with allosteric modulators may offer advantages over traditional treatments like baclofen [2] Company Overview - Addex's lead drug candidate, ADX71149, is a positive allosteric modulator developed in collaboration with Janssen Pharmaceuticals and has completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke recovery [3] - Addex is advancing a GABAB PAM program for chronic cough and has a partnership with Indivior for multiple drug candidates targeting substance use disorder [3] Research and Development - The upcoming presentation will focus on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models [1] - GABAB receptor activation has been clinically validated with baclofen, but its use is limited due to side effects and tolerance issues [2] - Allosteric modulators are expected to provide higher selectivity and better tolerability compared to orthosteric compounds [2]

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] Group 1: Company Overview - Addex Therapeutics is developing a portfolio of allosteric modulators targeting neurological disorders, with lead drug candidate ADX71149 having completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior for GABAB PAM programs, advancing multiple drug candidates for substance use disorder and an independent program for chronic cough [3] Group 2: GABAB Receptor and Chronic Cough - GABAB receptors are expressed in airways and the cough neural circuit, and their activation has been clinically validated with baclofen, a selective GABAB agonist [2] - Baclofen's use is limited due to side effects and loss of efficacy, while targeting an allosteric binding site of the GABAB receptor is expected to offer advantages like higher selectivity and better tolerability [2]

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM). The votes represented 33.79% of the company's outstanding capital. Addex shareholders approved the 2023 annual report, the 2023 annual ...